{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:57:55Z","timestamp":1787896675417,"version":"build-2784847793"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.lanwpc.2023.100847","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:22:36Z","timestamp":1690330956000},"page":"100847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-4866","authenticated-orcid":false,"given":"Masaaki","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Hinoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-2417","authenticated-orcid":false,"given":"Takuya","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaya","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hatata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Naruto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hosoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-8877","authenticated-orcid":false,"given":"Satoshi","family":"Kusuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2023.100847_bib1","series-title":"RSV infection, IDWR issue No. 22","year":"2004"},{"issue":"5","key":"10.1016\/j.lanwpc.2023.100847_bib2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in\u00a0vitro and in\u00a0vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J\u00a0Infect Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.lanwpc.2023.100847_bib3","first-page":"531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.lanwpc.2023.100847_bib4","author":"AbbVie"},{"issue":"4","key":"10.1016\/j.lanwpc.2023.100847_bib5","first-page":"215","article-title":"Safety and pharmacokinetics of palivizumab administered in infants with a history of prematurity or chronic lung disease","volume":"50","author":"Takeuchi","year":"2002","journal-title":"J\u00a0Jpn Soc Chemother"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100847_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s10156-010-0121-1","article-title":"Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan","volume":"17","author":"Mori","year":"2011","journal-title":"J\u00a0Infect Chemother"},{"issue":"6","key":"10.1016\/j.lanwpc.2023.100847_bib7","first-page":"1046","article-title":"Analysis of nationwide survey of children requiring prevention of respiratory syncytial virus infection in Japan","volume":"113","author":"Mori","year":"2009","journal-title":"J\u00a0Jpn Pediatr Soc"},{"issue":"8","key":"10.1016\/j.lanwpc.2023.100847_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jiac.2014.05.001","article-title":"Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome","volume":"20","author":"Mori","year":"2014","journal-title":"J\u00a0Infect Chemother"},{"issue":"11","key":"10.1016\/j.lanwpc.2023.100847_bib9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/INF.0000000000000392","article-title":"Palivizumab use in Japanese infants and children with immunocompromised conditions","volume":"33","author":"Mori","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.lanwpc.2023.100847_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40272-017-0264-y","article-title":"Palivizumab prophylaxis against respiratory syncytial virus infection in children with immunocompromised conditions or Down syndrome: a multicenter, post-marketing surveillance in Japan","volume":"20","author":"Kashiwagi","year":"2018","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.lanwpc.2023.100847_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12887-021-02567-6","article-title":"Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection","volume":"21","author":"Mori","year":"2021","journal-title":"BMC Pediatr"},{"issue":"Suppl 3","key":"10.1016\/j.lanwpc.2023.100847_bib13","first-page":"1","article-title":"[Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines]","volume":"9","year":"2004","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lanwpc.2023.100847_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"2\u20133","key":"10.1016\/j.lanwpc.2023.100847_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1386-5056(00)00062-9","article-title":"The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM)","volume":"57","author":"Yokotsuka","year":"2000","journal-title":"Int J Med Inform"},{"issue":"11","key":"10.1016\/j.lanwpc.2023.100847_bib17","article-title":"Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children","volume":"11","author":"Garegnani","year":"2021","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606523001657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606523001657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:43:05Z","timestamp":1763001785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606523001657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":15,"alternative-id":["S2666606523001657"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100847","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100847"}}